Mayne Pharma’s Acquisition by Cosette Pharmaceuticals Moves Forward with Court Approval

Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.

Mayne Pharma Group Limited has announced that the Supreme Court of New South Wales has approved the convening of a shareholder meeting to consider a proposed acquisition by Cosette Pharmaceuticals, Inc. The meeting will allow shareholders to vote on the scheme of arrangement, which has been deemed fair and reasonable by an independent expert. The expert’s report values Mayne Pharma shares within a range that aligns with the proposed acquisition price, and the company’s directors unanimously recommend shareholders vote in favor of the scheme. The outcome of this acquisition could significantly impact Mayne Pharma’s operations and market positioning, providing potential benefits to stakeholders.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited is a pharmaceutical company based in Australia, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company operates within the healthcare industry and serves various markets with its diverse range of pharmaceutical offerings.

Average Trading Volume: 797,278

Technical Sentiment Signal: Hold

Current Market Cap: A$560.6M

See more data about MYX stock on TipRanks’ Stock Analysis page.